Aspire Biopharma Holdings (ASBP) EBT (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly EBT of -$3.2 million for Q1 2026, up 79.78% year-over-year from -$1.8 million in Q1 2025, and up 60.13% quarter-over-quarter from -$8.1 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) EBT (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported EBT for 3 consecutive years, with -$3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 79.78% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at -$29.9 million (changed N/A YoY), while the FY2025 annual figure was -$24.5 million, down 1770.4% from the prior year.
- EBT advanced to -$3.2 million in Q1 2026 per ASBP's latest filing, from -$8.1 million in the prior quarter.
- Across five years, EBT topped out at -$215256.0 in Q3 2024 and bottomed at -$15.9 million in Q1 2025.
- Historically, EBT has averaged -$5.1 million across 3 years, with a median of -$2.9 million in 2025.
- Annual changes were most pronounced in 2025 — EBT slumped 1257.0% — and 2026, when it surged 79.78%.
- Aspire Biopharma Holdings' EBT stood at -$595639.0 in 2024, then plunged by 1257.0% to -$8.1 million in 2025, then jumped by 60.13% to -$3.2 million in 2026.
- Business Quant data shows ASBP's EBT at -$3.2 million in Q1 2026, -$8.1 million in Q4 2025, and -$2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 81.49 Mn |
| 10 | Aspire Biopharma Holdings | 8.27 Mn | -3.90 Mn | -30,086.00 | -1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.27 Mn |
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -8.08 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Mar 31, 2025 | -15.94 Mn |
| Dec 31, 2024 | -595,639.00 |
| Sep 30, 2024 | -215,256.00 |